Akademik Veri Yönetim Sistemi
European Congress of Internal Medicine, İstanbul, Türkiye, 06 Mart 2024, (Tam Metin Bildiri)
Aim: In our study, we aimed to contribute to cancer studies in our country by investigating whether there was an increase in the incidence of incidental lung cancer detection in patients diagnosed with lung cancer in Ankara Bilkent City Hospital during the pandemic period compared to the pre-pandemic period and whether patients diagnosed with lung cancer had an earlier stage and lower mortality. Materials and Methods: In this study, we analysed the data of 196 patients with lung cancer who were followed up in the Medical Oncology department of Ankara Bilkent City Hospital between March 1, 2019 and March 1, 2021. Patient files and clinical characteristics were analysed. The mode of diagnosis, complaints at admission, diagnostic stage of incidental cases, disease course, mortality and clinical laboratory data were collected. The patients included in the study were divided into two groups according to the date of diagnosis: pre-pandemic and pandemic period. Conclusions: There was no statistically significant difference between the pre-pandemic and pandemic process groups in terms of initial complaints, methods of diagnosis, stages at the time of diagnosis, mortality rates and progression-free survival rates. In terms of mortality in lung cancer, progression in disease stage, high LDH and low albumin levels increase the mortality hazard ratio, while being diagnosed during the pandemic period does not affect the mortality hazard ratio. Especially in our centre, thanks to the measures taken for the COVID-19 pandemic, there was no disruption in the diagnosis, follow-up and treatment processes of patients with lung cancer.Keywords: lung cancer, COVID-19, clinical oncolo